A study of clinical and dermoscopic features in alopecia areata at a tertiary referral center

Nikhil, Nivedhitha; Mamatha, P; Hanumanthayya, K

doi:10.18203/issn.2455-4529.intjresdermatol20204457

Cited by 3 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with other studies 7,8 . Regarding scalp severity, S2 grade of severity represented 45% of the patients, followed by Grade S1 in 31% of patients, these findings are also documented in other studies 12,13 . There are several dermoscopic signs of alopecia areata including YDs, BDs, SVHs, EHs, and BHs (8,9,14).…”

Section: Discussionsupporting

confidence: 85%

Dermatoscopic evaluation of alopecia areata

Chalabi¹,

harbawi²,

Salman³

2021

Ann Coll Med Mosul

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Dermatoscopic evaluation of alopecia areata

Chalabi¹,

harbawi²,

Salman³

2021

Ann Coll Med Mosul

View full text Add to dashboard Cite

show abstract

“…Consequently, this immune response results in the unfortunate consequence of HL, leaving affected individuals with an altered appearance and potential psychological impact. 1 It is the second most common cause of HL worldwide. The condition can affect both males and females of any age, although it often begins in childhood or early adulthood.…”

Section: Introductionmentioning

confidence: 99%

“…The underlying cause of AA stems from the body's immune system mistakenly targeting and attacking the hair follicles (HFs). Consequently, this immune response results in the unfortunate consequence of HL, leaving affected individuals with an altered appearance and potential psychological impact 1 . It is the second most common cause of HL worldwide.…”

Section: Introductionmentioning

confidence: 99%

MiR‐200c‐3p as a novel genetic marker and therapeutic tool for alopecia areata

AbdElneam,

Al‐Dhubaibi,

Bahaj

et al. 2024

Skin Research and Technology

View full text Add to dashboard Cite

BackgroundMicroRNAs (miRNAs) are small RNA molecules that regulate gene expression in diverse biological processes. They hold promise as therapeutic candidates for targeting human disease pathways, although our understanding of their gene regulatory mechanism remains incomplete. Alopecia areata (AA) is a prevalent inflammatory ailment distinguished by the infiltration of T cells targeting the anagen‐stage hair follicles. The scarcity of effective remedies for AA may stem from limited understanding regarding its precise cellular mechanism.AimTo investigate and examine the importance and role of the miR‐200c‐3p as a genetic indicator for AA, and its possible impact on disease progression.Subjects and methodsCase‐control study included 65 patients with AA and 65 matched healthy controls. A real‐time PCR technique was used to measure the expression of miR‐200c‐3p for both groups. Bioinformatic tools were used for prediction with genes and gene‐gene interaction, and protein‐protein interaction.ResultsThe expression levels of miR‐200c‐3p were significantly higher in AA patients than in healthy controls. We predicted that miR‐200c‐3p plays a markable role in the development of AA by its effect on the EGFR tyrosine kinase inhibitor resistance pathway.ConclusionWe were able to identify the influence of miR‐200c‐3p on both PLCG1 and RPS6KP1 genes which in turn regulate the EGFR tyrosine kinases resistance pathway that displayed the most substantial increase in activity. Our outcomes shed light on the era of the potential theranostic role of this innovative miRNA in AA.

show abstract

Combined microneedling with topical vitamin D3 or bimatoprost versus microneedling alone in the treatment of alopecia areata: A comparative randomized trial

Ali

Hafiz

Ahmed

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Introduction: Alopecia areata (AA) is a challenging disease with variable treatment outcomes. Hair follicles express vitamin D receptors. Therefore, vitamin D3 may be promising for AA treatment through immunomodulatory mechanisms. The efficacy of bimatoprost in scalp AA treatment was reported by few studies. Objective: To evaluate the efficacy and safety of microneedling (MN) with topical vitamin D3 versus MN with bimatoprost in comparison with MN alone in the treatment of localized AA. Patients and Methods: Seventy-five patients with localized AA were divided into three groups. The first group: 25 patients were treated with MN alone. The second group: 25 patients treated with MN combined with topical vitamin D3. The third group: 25 patients treated with MN combined with bimatoprost solution. The response was evaluated clinically and dermoscopically.Results: At the end of the study, all groups showed a statistically significant decrease in the SALT score compared to the baseline. The clinical response (regrowth scale): vitamin D and bimatoprost groups showed a statistically significant higher regrowth scale compared to MN alone group (p-value = 0.000). After treatment, hair regrowth was significantly higher in MN combined with bimatoprost than in MN combined with topical vitamin D3. However, after 3 months of follow-up, there was no statistically significant difference between both groups. Side effects were mild and transient in all groups. Conclusion:Topical vitamin D3 and bimatoprost combined with MN are safe and effective therapeutic options for localized AA.

show abstract

A study of clinical and dermoscopic features in alopecia areata at a tertiary referral center

Cited by 3 publications

References 8 publications

Dermatoscopic evaluation of alopecia areata

Dermatoscopic evaluation of alopecia areata

MiR‐200c‐3p as a novel genetic marker and therapeutic tool for alopecia areata

Combined microneedling with topical vitamin D3 or bimatoprost versus microneedling alone in the treatment of alopecia areata: A comparative randomized trial

Contact Info

Product

Resources

About